Northwire Canada EditionFriday, October 16, 2026

Sign in Subscribe

GOLD 4188.20 +0.4% SILVER 57.13 −0.0% COPPER 6.57 +0.1% OIL 98.88 +0.9% PALLADIUM 1116.00 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% GOLD 4188.20 +0.4% SILVER 57.13 −0.0% COPPER 6.57 +0.1% OIL 98.88 +0.9% PALLADIUM 1116.00 −1.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% BVA 0.780 +2.6% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5%

Other

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

By The Northwire Desk — AI Analysis Feb 12, 2026 · 03:45 4565 · None None

4565 · Price

Executive Summary

Centessa Pharmaceuticals achieved an early development milestone for its OX2R agonist ORX489, triggering a $1.8 million payment to Nxera Pharma under their research collaboration.
The $1.8 M milestone will be recognized as revenue in Nxera’s first quarter of 2026, providing a material positive impact on the company’s near‑term financial results.
The announcement underscores progress in Nxera’s partnership pipeline and highlights ongoing development of neuropsychiatric disorder therapeutics.

Key Details

Milestone Achievement: Early development milestone for Centessa’s investigational oral OX2R agonist, ORX489 (targeting neuropsychiatric disorders).
Payment Amount: US$1.8 million payable to Nxera Pharma upon milestone completion.
Revenue Recognition: The payment will be recorded as revenue in Nxera’s Q1 2026 financial statements.
Collaboration Context: Payment is pursuant to the existing research collaboration agreement between Nxera Pharma and Centessa Pharmaceuticals.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from None

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions